KEYNOTE-564 and PROs From LITESPARK-005: Positive Data in RCC

Brian Rini, MD, FASCO, Vanderbilt-Ingram Cancer Center, highlights the latest positive data presented at the morning Oral Abstract session on the final day of this year’s American Society of Clinical Oncology Genitourinary Cancers Symposium.

KEYNOTE-564 long-term survival data and LITESPARK-005 patient-reported outcomes are the focus of his comments.